Hartford Business.com
February 11, 2012
Browse News by Topic
- Agriculture
- Architecture
- Banking & Finance
- Biotechnology
- Construction
- Economy
- Education
- Energy
- Government & Politics
- Health Care
- Insurance
- Legal
- Manufacturing
- Media & Marketing
- Nonprofits
- Real Estate
- Restaurant & Food
- Retail
- Small Business
- Technology
- Telecom
- Tourism
- Transportation
Data Products
To Do List
- Subscribe to the HBJ
- Check Out Digital Editions
- Signup for HBJ Today & eNews
- Get In The HBJ (PDF)
- View HBJ Business Profiles
- Get Your Company Listed in the HBJ
- View Book Of Lists Info
- Send Us A Press Release
- Add a Calendar Item
- Advertise in the HBJ
- Register for the CT Business Expo
- Update your account information
- View HBJ Special Projects
- Hartford Hardcover Book Details
- HBJ Custom Publishing Division
- Job Opportunities
Awards & Events
- Special Sections
- Event Photos
- Event Videos
- Event Radio Interviews
- 40 Under Forty
- 40 Under 40 Alumni
- Best Places to Work
- Business Champions
- Business Energy Summit
- CFO of the Year
- CT Business Expo
- e-Marketing & Technology Summit
- Health Care Heroes
- Lifetime Achievement
- Social Media Summit
- Women in Business
- Speak at an Event
- Intern with HBJ Events
- Sell Expo Exhibit Space
Alexion Pharmaceuticals Inc. was mum Tuesday on the reason for a sharp rise in the stock price of the Cheshire drug maker.
Bloomberg News reported earlier that Alexion shares had risen in response to a Goldman Sachs analysis that the early success of Alexion's sole drug, Soliris, may make it a takeover target for another drug company.
An Alexion spokesman said the company would not comment on the reports.
Soliris has approval from the United States, Europe, Australia and other countries to treat a rare blood disorder.
Alexion shares closed up 98 cents, or 1.9 percent, at $53.83.
Based on Tuesday's closing price, Alexion's market capitalization is $4.8 billion.
This article does not currently have any comments